The efficacy of fostatinib/fotantinib in the treatment of ITP

Fostamatinib has shown significant efficacy in the treatment of chronic immune thrombocytopenia (ITP). It is an oral small molecule tyrosine kinase inhibitor that provides an innovative option for refractory patients. The immune system of patients with ITP abnormally recognizes platelets and destroys them in an antibody-mediated manner, resulting in decreased platelet counts and increased risk of bleeding. Fotantinib blocks this immune destruction process by inhibiting the SYK (Spleen Tyrosine Kinase) signaling pathway, thereby helping the platelet count return to a safe level and reducing the incidence of spontaneous bleeding and ecchymosis. This mechanism of action is different from traditional glucocorticoid or intravenous immunoglobulin therapy, making it an important treatment option in chronic or refractory patients.

In actual use, fotantinib adopts an oral administration mode, which facilitates long-term maintenance treatment. Patients do not need to frequently go to the hospital for intravenous injections, thus significantly improving life convenience and treatment compliance. Patients need to regularly monitor platelet levels, blood pressure and liver function while taking the medication in order to detect possible adverse reactions in a timely manner and make dosage adjustments under the guidance of a doctor. The drug is generally well tolerated, and common mild to moderate side effects such as diarrhea, increased blood pressure, or mild headache can usually be controlled through symptomatic treatment or dose adjustment. Long-term observation shows that most patients are able to maintain stable platelet levels within a safe range, thereby reducing the risk of bleeding events and disease progression.

The therapeutic advantage of fotantinib also lies in its long-term sustainability in patients with chronicITP. Compared with the problems of drug resistance or unstable response that may occur with traditional therapies, fotantinib maintains platelet levels through continuous oral administration, providing a feasible long-term management solution for chronic patients. In international clinical practice, fotantinib not only increases platelet count, but also improves patients' quality of daily life, enabling patients to achieve disease management and self-care at home.

Reference materials:https://go.drugbank.com/drugs/DB12010